CML Highlights of the EHA2026 Congress
Hear from Professor Andreas Hochhaus and Associate Professor Kateřina Machová Poláková about the CML Highlights of EHA2026
Clinical overview
Expert
Professor Andreas Hochhaus
Director of the Department of Hematology and Medical Oncology,
Jena University Hospital
Jena, Germany
Program
Overview of significant clinical aspects presented during the meeting, including:
- ASC4FIRST week 144 analysis [10:02]
- ENABLE: Updated efficacy and safety results of ELVN-001 [14:37]
- ASC4Kids-2 trial-in-progress: Asciminib in pedriatric CML [18:29]
- NAUT Study (CML VIII) [10:11]
Biological overview
Expert
Associate Professor Kateřina Machová Poláková
1st Medical Faculty, Charles University /
Head, Department of Molecular Genetics and the Biobank,
Institute of Haematology and Blood Transfusion
Prague, Czechia
Program
Overview of significant biological aspects presented during the meeting, including:
- The crosstalk between CML and the niche [03:49]
- Myelofibrosis at diagnosis is associated with outcome after TKI cessation [04:52]
- SC transcriptomics-guided flow cytometric analysis of inflamed megakaryocytic and lymphoid progenitors at diagnosis identifies chronic-phase CML at high risk for blast crisis transformation [07:09]
- Molecular mechanisms of ZDHHC19-mediated JAK1 palmitoylation driving TKI resistance in CML leukemia stem cells [11:35]
- Influence of non-BCR::ABL1 somatic mutations on TKI resistance in CML [15:13]
- PDX models to predict response to drug combinations in blast crisis CML [18:36]
- Q&A Session [22:18]
